Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.

Genital herpes is one of the most common sexually transmitted diseases worldwide. Currently, there are three FDA-approved nucleoside analogs and other therapies such as foscarnet and cidofovir used to treat genital herpes. Resiquimod, the latest immune response modifier (IRM), has shown in vivo evidence of efficacy against herpes simplex virus (HSV) type 2. The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trials were suspended due to lack of efficacy. Resiquimod shows promise for other viral infections and as a vaccine adjuvant.
AuthorsJashin J Wu, David B Huang, Stephen K Tyring
JournalAntiviral research (Antiviral Res) Vol. 64 Issue 2 Pg. 79-83 (Nov 2004) ISSN: 0166-3542 [Print] Netherlands
PMID15498602 (Publication Type: Journal Article, Review)
Chemical References
  • Adjuvants, Immunologic
  • Imidazoles
  • Viral Vaccines
  • resiquimod
  • Adjuvants, Immunologic (administration & dosage)
  • Adult
  • Animals
  • Guinea Pigs
  • Herpes Genitalis (drug therapy, immunology, virology)
  • Herpesvirus 2, Human (drug effects)
  • Humans
  • Imidazoles (administration & dosage, immunology)
  • Th1 Cells (immunology)
  • Viral Vaccines (administration & dosage, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: